Coming Soon

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR

To evaluate the safety, optimum drug usage, and anti tumor activity for the drug BDTX-1535.

Age & Gender

18 years ~ 99 years
Male, Female

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

24-0821

ClinicalTrials.gov

NCT05256290

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

My UNC Chart
Find a Doctor
Accessibility
Privacy Policy
For Researchers

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.